Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.22.2.2
Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Balance $ 1,701,770  
Balance 1,751,154  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance 8,069 $ (6,193)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 4,376 84
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 319 1,598
Balance 12,764 (4,511)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance (83,269) (51,098)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (21,457) (8,607)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)   0
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance (104,574) (59,705)
AOCI Attributable to Parent [Member]    
Balance (75,200) (57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (17,081) (8,523)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 319 1,598
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152  
Balance $ (91,810) $ (64,216)